Vanda Pharmaceuticals | VNDA - Interest Expense On Debt

Stock Price
7.21
Daily Change
0.39 5.72%
Monthly
-16.16%
Yearly
51.15%
Q1 Forecast
6.91

Vanda Pharmaceuticals reported 601.14M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 4.83M 359.32M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Esperion Therapeutics USD 22.64M 585K Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.6M 217K Dec/2025
J&J USD 18M 290M Sep/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Takeda JPY 123.63B 40.49B Dec/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025
Veracyte USD 2K 1000 Dec/2023